Sab Biotherapeutics Inc (SABS) Stock Price, Quote & News

Latest News on SABS

Mar 31, 2025, 7:32 AM EDT - 19 days ago

SAB BIO Reports Full Year 2024 Operating and Financial Results

Jan 31, 2025, 7:00 AM EST - 2 months ago

SAB BIO to Participate in Upcoming Investor Conferences

Jan 28, 2025, 3:40 PM EST - 2 months ago

Why Is SAB BIO Stock Trading Lower On Tuesday?

Jan 28, 2025, 7:00 AM EST - 2 months ago

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

Jan 23, 2025, 7:00 AM EST - 3 months ago

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

Nov 6, 2024, 5:05 PM EST - 5 months ago

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

Sep 13, 2024, 7:00 AM EDT - 7 months ago

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

Sep 4, 2024, 7:05 AM EDT - 8 months ago

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

Aug 8, 2024, 5:51 PM EDT - 9 months ago

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

Aug 5, 2024, 7:30 AM EDT - 9 months ago

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

Jul 31, 2024, 7:30 AM EDT - 9 months ago

SAB BIO Appoints Lucy To as Chief Financial Officer

Jun 20, 2024, 7:20 AM EDT - 10 months ago

SAb Biotherapeutics Rebrands as SAB BIO

Jun 18, 2024, 1:10 PM EDT - 10 months ago

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

May 30, 2024, 4:45 PM EDT - 11 months ago

SAB Biotherapeutics Announces Departure of Chief Financial Officer

May 21, 2024, 7:15 AM EDT - 11 months ago

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

May 20, 2024, 5:45 PM EDT - 11 months ago

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

May 6, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

Apr 16, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics Provides SAB-142 Trial Update

Apr 8, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics to Present at INNODIA Annual Meeting

Apr 4, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

Mar 29, 2024, 7:15 AM EDT - 1 year ago

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Mar 25, 2024, 10:15 AM EDT - 1 year ago

SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment

Feb 23, 2024, 8:00 AM EST - 1 year ago

SAB Biotherapeutics to Present at the BIO CEO & Investor Conference

Feb 8, 2024, 8:00 AM EST - 1 year ago

SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 2, 2024, 7:30 AM EST - 1 year ago

SAB Biotherapeutics Announces Executive Leadership Change

Jan 23, 2024, 5:58 PM EST - 1 year ago

SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jan 2, 2024, 4:30 PM EST - 1 year ago

SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split

Nov 29, 2023, 7:30 AM EST - 1 year ago

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

Nov 20, 2023, 7:30 AM EST - 1 year ago

SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors

Nov 14, 2023, 7:30 AM EST - 1 year ago

SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes

Nov 14, 2023, 7:15 AM EST - 1 year ago

SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates

Nov 9, 2023, 7:30 AM EST - 1 year ago

SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference

Oct 24, 2023, 7:30 AM EDT - 1 year ago

SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer

Oct 19, 2023, 7:30 AM EDT - 1 year ago

SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

Oct 5, 2023, 7:30 AM EDT - 1 year ago

SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors

Oct 2, 2023, 7:30 AM EDT - 1 year ago

SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes

Aug 21, 2023, 8:30 AM EDT - 1 year ago

SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results

Jun 21, 2023, 8:30 AM EDT - 1 year ago

SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023

May 30, 2023, 8:30 AM EDT - 2 years ago

SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention

May 19, 2023, 8:30 AM EDT - 2 years ago

Market Cap	12.82M
Revenue (ttm)	1.32M
Net Income (ttm)	-34.11M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,584.09%
Debt to Equity Ratio	0.00

Volume	800
Avg Vol	60,518
Day's Range	N/A - N/A
Shares Out	9.29M
Stochastic %K	90%
Beta	0.52
Analysts	Strong Sell
Price Target	$10.60